Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABVC | ABVC BioPharma, Inc.

Index	-	P/E	-	EPS (ttm)	-3.84	Insider Own	38.99%	Shs Outstand	3.31M	Perf Week	-11.76%
Market Cap	4.20M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.66M	Perf Month	-47.50%
Income	-12.70M	PEG	-	EPS next Q	-	Inst Own	2.00%	Short Float / Ratio	0.75% / 0.02	Perf Quarter	-82.20%
Sales	0.80M	P/S	5.25	EPS this Y	-1.20%	Inst Trans	-91.94%	Short Interest	0.02M	Perf Half Y	-83.85%
Book/sh	-0.11	P/B	-	EPS next Y	-	ROA	-125.30%	Target Price	-	Perf Year	-86.00%
Cash/sh	0.05	P/C	21.00	EPS next 5Y	-	ROE	-491.10%	52W Range	1.03 - 18.70	Perf YTD	-83.20%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-320.40%	52W High	-94.39%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	46.50%	52W Low	1.94%	ATR	0.22
Employees	19	Current Ratio	0.40	Sales Q/Q	-98.00%	Oper. Margin	-	RSI (14)	30.17	Volatility	11.30% 11.91%
Optionable	No	Debt/Eq	-	EPS Q/Q	-15.20%	Profit Margin	-	Rel Volume	0.06	Prev Close	1.09
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 31 AMC	Payout	-	Avg Volume	811.78K	Price	1.05
Recom	3.00	SMA20	-19.35%	SMA50	-56.37%	SMA200	-81.67%	Volume	49,228	Change	-3.67%

Aug-23-23 08:30AM	ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study (GlobeNewswire)
Aug-17-23 09:19AM	ABVC Executes Cooperation Agreement for Strategic Investments (GlobeNewswire) -7.22%
Aug-10-23 08:30AM	ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement (GlobeNewswire) -8.82%
Aug-07-23 08:30AM	ABVC Corporate Update and CEO's Letter to Shareholders (GlobeNewswire) -5.47%
Aug-03-23 09:20AM	ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration (GlobeNewswire)
08:30AM	Loading…
Aug-01-23 08:30AM	ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales (GlobeNewswire) +44.98%
Jul-31-23 09:30AM	ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering (GlobeNewswire) -7.43%
Jul-27-23 09:22AM	ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering (GlobeNewswire) -41.73%
Jul-26-23 08:30AM	ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments (GlobeNewswire) +40.00%
Jul-24-23 12:30PM	ABVC BioPharma Announces Reverse Stock Split (GlobeNewswire)
Jul-06-23 08:30AM	The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency (GlobeNewswire) -6.49%
Jun-26-23 08:30AM	ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth (GlobeNewswire) +7.54%
Jun-20-23 08:30AM	ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production (GlobeNewswire) +7.90%
Jun-12-23 08:30AM	ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF (GlobeNewswire)
Jun-06-23 08:30AM	ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization (GlobeNewswire)
08:30AM	Loading…
May-22-23 08:30AM	ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia (GlobeNewswire) -5.42%
May-04-23 08:30AM	ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder (GlobeNewswire)
Apr-26-23 08:30AM	ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF (GlobeNewswire)
Apr-10-23 08:30AM	ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC) (GlobeNewswire)
Apr-06-23 08:30AM	ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand (GlobeNewswire)
Mar-31-23 06:49PM	ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results (GlobeNewswire)
Mar-20-23 07:00AM	ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand (PR Newswire) +8.32%
Mar-14-23 07:00AM	ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare (PR Newswire) +11.21%
Feb-28-23 08:30AM	ABVC BioPharma Provides 2023 Pipeline Update (GlobeNewswire)
Feb-23-23 04:16PM	ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials (GlobeNewswire)
Feb-21-23 08:30AM	ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus® (GlobeNewswire) +6.21%
Jan-19-23 08:30AM	ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference (GlobeNewswire)
Jan-18-23 08:25AM	ABVC: Several Potential Paths to Achieving Near-Term Milestones (Zacks Small Cap Research) -6.04%
Jan-05-23 08:30AM	FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer (GlobeNewswire) +72.58%
Dec-20-22 11:05AM	ABVC: Key Medical Venues Participating in Clinical Studies (Zacks Small Cap Research)
08:30AM	Loading…
Nov-17-22 08:30AM	ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval (GlobeNewswire)
05:16AM	ABVC BioPharma Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 06:20PM	ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results (GlobeNewswire)
Nov-07-22 08:30AM	ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD) (GlobeNewswire)
Nov-02-22 08:30AM	Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharmas Medication for Treating Depression in Cancer Patients (GlobeNewswire)
Oct-05-22 08:30AM	ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia (GlobeNewswire)
Sep-23-22 08:30AM	ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval (GlobeNewswire) +12.72%
Sep-16-22 09:36AM	ABVC: Moving Lead Assets Forward and Expanding Development Pipeline (Zacks Small Cap Research) -27.00%
Sep-13-22 08:30AM	ABVC Biopharma Announces Letter to Shareholders (GlobeNewswire)
Sep-09-22 08:30AM	ABVC BioPharma Selects Additional Vitargus® Phase II Study Site (GlobeNewswire)
Aug-22-22 08:30AM	ABVC Provides Oncology Pipeline Updates (GlobeNewswire)
Aug-18-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire) +19.62%
Aug-15-22 05:48PM	ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results (GlobeNewswire) -5.76%
Aug-02-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire)
Jul-18-22 08:30AM	ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028 (GlobeNewswire)
Jul-13-22 08:30AM	ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update (GlobeNewswire)
Jul-06-22 08:30AM	Zacks Places Share Value of ABVC BioPharma at $9.50 (GlobeNewswire)
Jun-30-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire)
Jun-21-22 08:30AM	ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation (GlobeNewswire)
Jun-16-22 08:30AM	ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC (GlobeNewswire)
Jun-10-22 08:30AM	ABVC BioPharma Announces Termination of Two Contracts (GlobeNewswire) -47.37%
Jun-07-22 01:10PM	ABVC: Enrollment in ABV-1505 Part 2 ADHD Clinical Study Continues; First Patient Begins Treatment (Zacks Small Cap Research)
Jun-01-22 08:30AM	ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study (GlobeNewswire)
May-25-22 08:30AM	ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners (GlobeNewswire)
May-23-22 07:30AM	Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines (GlobeNewswire)
May-16-22 05:46PM	ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results (GlobeNewswire) -5.78%
03:25PM	WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering (PR Newswire)
May-13-22 08:30AM	ABVC BioPharma Engages the FreeMind Group to Support Grant Funding (GlobeNewswire) +6.13%
May-12-22 09:00AM	WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering (PR Newswire) -13.47%
08:30AM	ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering (GlobeNewswire)
May-10-22 08:30AM	ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated (GlobeNewswire) +8.24%
May-05-22 08:30AM	ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process (GlobeNewswire)
May-03-22 08:30AM	ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed (GlobeNewswire)
Apr-28-22 08:30AM	ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study (GlobeNewswire)
Apr-26-22 08:30AM	ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting (GlobeNewswire)
Mar-31-22 04:18PM	ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results (GlobeNewswire)
Mar-23-22 09:25AM	ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-08-22 06:15AM	ABVC: Lead Products Move Closer To Potential Approval; Important Clinical Studies Advancing (Zacks Small Cap Research)
Feb-02-22 08:00AM	ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study (GlobeNewswire)
Jan-05-22 08:30AM	ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites (GlobeNewswire)
Dec-22-21 08:30AM	ABVC BioPharmas Vitreous Substitute Vitargus Presented at 14th APVRS Congress (GlobeNewswire)
Dec-15-21 08:30AM	ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award (GlobeNewswire) +8.85%
Dec-10-21 01:38PM	Why ABVC BioPharma Shares Are Trading Higher On Friday? (Benzinga) +5.14%
05:17AM	ABVC: Moving Forward on Several 2022 Goals to Advance Growth Strategy (Zacks Small Cap Research)
Dec-09-21 08:30AM	ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement (GlobeNewswire)
Nov-15-21 04:33PM	ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results (GlobeNewswire) +7.23%
Nov-11-21 09:00AM	ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M (GlobeNewswire)
Nov-03-21 11:18AM	10 Best Stocks For Day Trading (Insider Monkey) -7.42%
Nov-02-21 06:18AM	What Percentage Of ABVC BioPharma, Inc. (NASDAQ:ABVC) Shares Do Insiders Own? (Simply Wall St.) -26.20%
Nov-01-21 11:32AM	ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today (InvestorPlace) +137.40%
10:51AM	What's Going On With ABVC BioPharma's Stock Today? (Benzinga)
10:21AM	Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg)
07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:03AM	28 Stocks Moving in Monday's Pre-Market Session (Benzinga)
Oct-27-21 08:30AM	Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites (GlobeNewswire)
Oct-15-21 12:05PM	33 Stocks Moving In Friday's Mid-Day Session (Benzinga) +10.16%
07:03AM	22 Stocks Moving in Friday's Pre-Market Session (Benzinga)
Oct-12-21 08:30AM	ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research (GlobeNewswire) +10.09%
Sep-13-21 08:30AM	ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study (GlobeNewswire) -6.54%
Sep-01-21 03:54PM	Why ABVC BioPharma Shares Are Trading Higher Today (Benzinga) +23.79%
08:30AM	ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments (GlobeNewswire)
Aug-30-21 08:30AM	ABVC BioPharma Report Updated by Zacks/SCR (GlobeNewswire) +7.07%
Aug-26-21 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire) +16.67%
05:00AM	ABVC: Company Continues to Advance Lead Assets & Earlier Stage Candidates (Zacks Small Cap Research)
Aug-12-21 08:27AM	ABVC BioPharma Reports Second Quarter 2021 Results (GlobeNewswire) -24.30%
Aug-06-21 08:30AM	WallachBeth Capital Announces the Completion of an Underwritten Public Offering of 1,100,000 Units for ABVC BioPharma, Inc. (PR Newswire)
Aug-03-21 08:30AM	ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering (GlobeNewswire) -39.60%
Jun-09-21 10:20AM	ABVC: Enhancing Financial Flexibility To Support Growth Strategy (Zacks Small Cap Research)
Jan-27-21 04:55AM	ABVC: Developing a Growing Portfolio Of Plant-Based Therapies With Strong Prospects (Zacks Small Cap Research)
Jan-06-21 09:00AM	American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021 (GlobeNewswire)

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABVC | ABVC BioPharma, Inc.

Upgrade your FINVIZ experience